Velázquez-Castañeda R, Fraind-Maya G, Pérez-Arce R, Lassard-Rosenthal J, García-Linage R, Zimbrón-López D

Language: Spanish
References: 11
Page: 326-330
PDF size: 599.53 Kb.

ABSTRACT

Introduction: tenosynovial giant cell tumor (TGCT) is a rare benign neoplastic condition affecting joint synovia, bursae, and tendon sheaths. It is classified as localized or diffuse based on clinical and biological behavior. Localized forms often affect small joints like fingers (85%), while diffuse forms primarily involve large joints, particularly the knee. Diffuse forms are more aggressive and can exceptionally exhibit malignancy. Case report: a 27-year-old male presented with a 2-year history of intermittent knee locking and reduced mobility, worsening after a sports-related trauma. MRI showed hyperintense nodular lesions in the posterior capsule of the knee. Arthroscopy confirmed a mass adherent to the posterior capsule, which was excised and pathologically diagnosed as localized TGCT. The patient was discharged home without complications 24 hours' post-surgery, and a 6-month follow-up MRI showed no significant findings. Currently, the patient has full range of motion and no limitations in physical activity. Conclusions: TGCT diagnosis can be challenging due to variable presentation and nonspecific symptoms, often mimicking meniscal tears. MRI is crucial for diagnosis and surgical planning. Localized forms are managed with arthroscopic excision, yielding low recurrence rates (0-10%) and excellent outcomes. Diffuse forms may require adjuvant radiotherapy or pharmacological treatments in refractory cases.

REFERENCES

1. Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017; 103(1S): S91-S97.

2. Krasic J, Skara L, Bojanac AK, Ulamec M, Jezek D, Kulis T, et al. The utility of cfDNA in TGCT patient management: a systematic review. Ther Adv Med Oncol. 2022; 14: 17588359221090365.

3. Sbaraglia M, Gambarotti M, Businello G, Righi A, Fassan M, Dei Tos AP. Intra-articular tumors. Surg Pathol Clin. 2021; 14(4): 665-677.

4. Spierenburg G, van der Heijden L, van Langevelde K, Szuhai K, Bovée JVGM, van de Sande MAJ, et al. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opin Ther Targets. 2022; 26 (4): 333-345.

5. Kager M, Kager R, Fa?ek P, Fa?ek A, Szczypiór G, Niemunis-Sawicka J, et al. Tenosynovial giant cell tumor. Folia Med Cracov. 2022; 62(2): 93-107.

6. Noailles T, Brulefert K, Briand S, Longis PM, Andrieu K, Chalopin A, et al. Giant cell tumor of tendon sheath: Open surgery or arthroscopic synovectomy? A systematic review of the literature. Orthop Traumatol Surg Res. 2017; 103(5): 809-814.

7. Cuevas-Estrada B, Montalvo-Casimiro M, Munguia-Garza P, Ríos-Rodríguez JA, González-Barrios R, Herrera LA. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in TGCT patients. Int J Mol Sci. 2023; 24(9): 7873.

8. Travis LB, Feldman DR, Fung C, Poynter JN, Lockley M, Frazier AL. Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship. J Clin Oncol. 2024; 42(6): 696-706.

9. Cassier P, Gelderblom H, Stacchiotti S, Thomas D, Maki R, Kroep J, et al. Efficacy of Imatinib Mesylat for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012; 118(6): 1649-1656.

10. Siegel M, Bode L, Südkamp N, Kühle J, Zwingmann J, Schmal H, et al. Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis. PLoS One. 2021; 16(12): e0260795.

11. Al-Ibraheemi A, Ahrens WA, Fritchie K, Dong J, Oliveira AM, Balzer B, et al. Malignant tenosynovial giant cell tumor: the true "synovial sarcoma?" A clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes. Mod Pathol. 2019; 32(2): 242-251.

EVIDENCE LEVEL

IV